Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, with news flow that reflects activity across its Affordable Medicines, Specialty, and AvKARE segments. This page aggregates company-specific coverage so readers can follow how Amneal’s development, manufacturing, and distribution efforts translate into regulatory milestones, clinical results, and financial performance.
News about Amneal frequently centers on U.S. FDA approvals and regulatory updates. Recent announcements include approvals for denosumab biosimilars referencing Prolia and XGEVA, epinephrine injection in single- and multi-dose vials for hospitals, iohexol injection as a first generic version of Omnipaque, albuterol sulfate inhalation aerosol as a generic equivalent of PROAIR HFA, and cyclosporine ophthalmic emulsion 0.05% as a generic equivalent of RESTASIS. These items illustrate the company’s focus on complex injectables, biosimilars, respiratory therapies, and ophthalmic products within its Affordable Medicines segment.
In the Specialty segment, news coverage highlights branded CNS and endocrine therapies, particularly CREXONT for Parkinson’s disease. Amneal has reported positive interim Phase 4 ELEVATE-PD results and emphasizes CREXONT’s role in improving motor symptom control and "Good On" time. The company also reports on collaborations, such as a research collaboration and option agreement with KeifeRx to advance KFRX06, a brain-penetrant LRRK2 program for Parkinson’s disease.
Investors and analysts will also find financial results and capital markets updates, including quarterly earnings releases, guidance updates, and details of term loan and senior secured notes financings. Governance and corporate events, such as participation in healthcare investor conferences and board changes, are disclosed through press releases and Form 8-K filings.
For users tracking AMRX, this news feed provides a centralized view of regulatory decisions, product launches, clinical data, financing transactions, and strategic collaborations that shape Amneal’s business across its three segments.
Amneal Pharmaceuticals (NYSE: AMRX) announced that the FDA accepted its 505(b)(2) New Drug Application for a dihydroergotamine (DHE) prefilled syringe autoinjector. A decision is expected by mid-2022, with a potential launch in the second half of 2022. This product aims to provide patients with an easy-to-use self-administration method for acute migraine and cluster headaches. DHE's current U.S. sales are around $70 million annually, indicating a significant market opportunity. Amneal's strategy includes leveraging its existing commercial infrastructure in neurology.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in two investor conferences. The RBC Global Healthcare Conference will be held on May 18, 2021, featuring a fireside chat at 1:55 p.m. ET. The Goldman Sachs 42nd Annual Global Healthcare Conference is scheduled for June 10, 2021, with a fireside chat at 3:50 p.m. ET. Both events will be accessible via live webcast on the Company's Investor Relations webpage. Amneal focuses on the development and distribution of generics and specialty products and holds a 65% stake in AvKARE.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) reported net revenue of $493 million for Q1 2021, a 1% decrease from $499 million in Q1 2020. The decline was attributed to reduced influenza activity and prior year customer purchases due to COVID-19. Net income fell to $7 million from $115 million, impacted by a $110 million tax benefit in 2020. Adjusted EBITDA was $126 million, down 6%. However, Amneal maintains its full-year 2021 guidance: net revenue of $2.1-$2.2 billion and adjusted diluted EPS of $0.70-$0.85.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2021 financial results on May 7, 2021, before market open. A conference call will be held at 8:30 a.m. Eastern Time on the same day, accessible via the Investor Relations section of their website. Access the call at (844) 746-0741 for U.S. callers or (412) 317-5273 internationally. A replay will be available for seven days after the call. Amneal focuses on the development and distribution of generic and specialty pharmaceuticals, with significant operations in North America, Asia, and Europe.
Amneal Pharmaceuticals (NYSE: AMRX) has completed the acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, enhancing its portfolio in complex generics and innovative drug delivery platforms. This move strengthens Amneal's R&D capabilities by integrating Kashiv's experienced team known for successful products like Yuvafem and EluRyng. The acquisition aligns with Amneal's strategy to evolve into a more integrated pharmaceutical company.
Amneal Pharmaceuticals (NYSE: AMRX) reported strong financial results for Q4 and full year 2020, with Q4 revenue at $510 million, a 28% increase year-over-year. The annual revenue reached $1.993 billion, up 23%. The company's net loss for Q4 improved to $3 million from $32 million in 2019, while net income for the year was $91 million compared to a loss of $362 million in 2019. Looking ahead, Amneal forecasts 2021 revenues between $2.1 billion and $2.2 billion and adjusted diluted EPS of $0.70 to $0.85, reflecting continued growth in the Generics and Specialty markets.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in two upcoming investor conferences: the Raymond James Institutional Investors Conference on March 1, 2021, at 3:00 p.m. ET, and the Barclays Global Healthcare Conference on March 10, 2021, at 4:10 p.m. ET. Both events will include fireside chats and can be accessed via a live webcast on the Company's Investor Relations website. Amneal focuses on developing and distributing generic and specialty pharmaceuticals, boasting around 250 product families, and operates globally, including a majority stake in AvKARE, which supplies pharmaceuticals to government agencies.
Amneal Pharmaceuticals (NYSE: AMRX) is set to release its fourth quarter and full year 2020 financial results on February 26, 2021, before market open. A conference call and live webcast will take place at 8:30 a.m. ET that day, accessible via the Investor Relations section of Amneal's website. Participants can join by dialing (844) 746-0741 in the U.S. or (412) 317-5273 internationally. A replay will be available for seven days at (877) 344-7529 for U.S. callers and (412) 317-0088 for international callers, using access code 10152029.
Amneal Pharmaceuticals (NYSE:AMRX) has announced a definitive agreement to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, enhancing its growth strategy. The $70 million upfront payment, plus $30 million after a year and potential contingent payments of $8 million, aims to boost Amneal's pipeline in neurology and endocrinology. This acquisition is expected to deliver approximately $15 million in annual adjusted EBITDA. The deal strengthens Amneal's R&D capabilities and is expected to close in Q2 2021, subject to regulatory approval.
Amneal Pharmaceuticals (NYSE: AMRX) announced FDA approval for a 500 mg strength of its Abiraterone Acetate Tablets, a generic version of Zytiga® for metastatic prostate cancer. This approval follows the existing 250 mg strength and allows for use in combination with Prednisone. Amneal has initiated commercialization for this additional strength, which could tap into the U.S. market valued at approximately $413 million annually, as reported by IQVIA™.
FAQ
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
What is the market cap of Amneal Pharmaceuticals (AMRX)?
